This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
Journal Club
Clinical Paper of the Month - Clinical outcomes in cytomegalovirus-positive posner-schlossman syndrome patients treated with topical ganciclovir therapy
Clinical outcomes in cytomegalovirus-positive posner-schlossman syndrome patients treated with topical ganciclovir therapy

Publishing date: December 2014

Author(s): Su CC(1), Hu FR(2), Wang TH(2), Huang JY(2), Yeh PT(2), Lin CP(2), Wang IJ(3)

1 Department of Ophthalmology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan; Department of Ophthalmology, National Taiwan University Hospital College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
2 Department of Ophthalmology, National Taiwan University Hospital College of Medicine, National Taiwan University, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei, Taiwan.
3 Department of Ophthalmology, National Taiwan University Hospital College of Medicine, National Taiwan University, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei, Taiwan; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan. Electronic address: ijong@ms8.hinet.net.

PURPOSE: To evaluate the clinical characteristics and therapeutic outcomes of cytomegalovirus (CMV)-positive Posner-Schlossman syndrome patients undergoing topical ganciclovir treatment.

DESIGN: Retrospective, comparative, and interventional case series.

METHODS: One eye of each of 126 consecutive Posner-Schlossman syndrome patients was investigated using aqueous polymerase chain reaction (PCR) between January 2006 and June 2013. The initial presentations and follow-up data of the CMV-positive patients (68 eyes) and CMV-negative patients (58 eyes) were compared.

RESULTS: Severe endothelial cell loss (P < .001) and a higher number of eyes requiring glaucoma filtering surgery (P = .017) were observed in CMV-positive Posner-Schlossman syndrome patients. All CMV-infected eyes treated with continual topical 2% ganciclovir exhibited an undetectable CMV level at the following taps. During follow-up, the average number of antiglaucomatous agents decreased, and a similar frequency of intraocular pressure (IOP) spikes was observed in both groups (P = .358). Patients with CMV-positive eyes with a disease duration over 5 years were likely to require glaucoma surgery (P = .024, log-rank test). All patients receiving surgery exhibited CMV-negative PCR during the IOP attack, but experienced severe peripheral anterior synechiae and pigment clogging. Both groups exhibited a similar endothelial cell decrease (P = .243) and probability of progressive endothelial cell loss (P = .219, log-rank test).

CONCLUSION: Ganciclovir treatment was effective for clearing the viral load, assisting the IOP control, and preserving the corneal endothelium of CMV-positive Posner-Schlossman syndrome patients. Early diagnosis and proper treatment could decrease the risk of advanced glaucoma and avoid glaucoma surgery in long-lasting cases.

Copyright © 2014 Elsevier Inc. All rights reserved.

Am J Ophthalmol. 2014 Nov;158(5):1024-1031.e2. doi: 10.1016/j.ajo.2014.08.007. Epub 2014 Aug 12

PMID: 25124264
http://www.ncbi.nlm.nih.gov/pubmed/25124264



Clinical Paper of the Month manager: Andreas Boehm




back to top

X